Chromo Immunohistochemistry at Test Zone Diagnostic Center

Chromo Immunohistochemistry at Test Zone Diagnostic Center

Chromo Immunohistochemistry (IHC) is a highly specialized, state-of-the-art diagnostic technique performed at Test Zone Diagnostic Center in Sargodha, Pakistan. This advanced laboratory investigation combines anatomical, immunological, and biochemical methods to identify specific cellular components (antigens) within tissue sections. By utilizing custom-engineered antibodies that bind selectively to target proteins, and visualizing this interaction through a localized chemical reaction that produces a distinct color, pathologists can diagnose diseases with unprecedented precision. Unlike routine histopathology, which relies solely on the morphological appearance of cells under hematoxylin and eosin (H&E) staining, Chromo IHC provides a molecular-level map of the tissue, revealing the functional and genetic characteristics of abnormal cells.

The technology behind Chromo Immunohistochemistry is both elegant and complex. It relies on the highly specific binding affinity between an antigen and an antibody. When a tissue biopsy is obtained, it is processed, embedded in paraffin wax, and cut into ultra-thin sections. These sections are then exposed to primary antibodies designed to target specific diagnostic markers, such as cytokeratins, hormone receptors, or oncogene products. To visualize this binding, a secondary antibody conjugated with an enzyme—typically horseradish peroxidase (HRP) or alkaline phosphatase (AP)—is introduced. Finally, a chromogenic substrate, such as diaminobenzidine (DAB) or Aminoethylcarbazole (AEC), is applied. The enzyme catalyzes the substrate to produce a stable, insoluble colored precipitate (brown for DAB, red for AEC) at the exact site of the antigen-antibody complex. This color change is easily visible under a standard brightfield light microscope, allowing the Consultant Pathologist at Test Zone Diagnostic Center to evaluate the presence, intensity, and localization of the target proteins.

The clinical importance of Chromo Immunohistochemistry cannot be overstated. It serves as the cornerstone of modern oncology, pathology, and personalized medicine. By evaluating the cellular and molecular profile of tumors, Chromo IHC enables precise tumor typing, helps determine the primary origin of metastatic cancers, assesses prognostic indicators, and predicts patient response to targeted therapies. This diagnostic value directly translates into more accurate treatment plans, minimizing the risk of misdiagnosis and ensuring that patients receive the most effective, tailored therapeutic interventions.

Clinical Procedure: What to Expect

Patient Preparation

Because Chromo Immunohistochemistry is a laboratory test performed on tissue samples that have already been collected, patient preparation primarily relates to the initial biopsy procedure or the submission of existing tissue blocks. Please observe the following guidelines:

• Submission of Existing Blocks: If you are bringing a previously collected tissue sample to Test Zone Diagnostic Center, ensure you obtain the Formalin-Fixed Paraffin-Embedded (FFPE) tissue block and the corresponding routine histopathology (H&E) slides from the referring laboratory. Keep these samples at room temperature; do not expose them to extreme heat or direct sunlight.
• Biopsy Preparation: If the biopsy is to be performed at our facility or an affiliated clinical site, follow specific instructions provided by your physician. This may include fasting for 6 to 8 hours if conscious sedation or general anesthesia is required.
• Medication Management: Inform your healthcare provider of all medications you are currently taking. Blood thinners, such as aspirin, clopidogrel, or warfarin, may need to be temporarily discontinued a few days before a biopsy to minimize bleeding risks.
• Medical Records: Always bring your complete medical history, previous imaging reports (such as CT, MRI, or ultrasound scans), and prior pathology reports to Test Zone Diagnostic Center to assist our pathologists in clinical correlation.

During the Procedure

The laboratory phase of Chromo Immunohistochemistry is a meticulous, multi-step process conducted by skilled histotechnologists and evaluated by Consultant Pathologists. The procedure involves the following clinical and technical stages:

• Specimen Reception and Verification: The tissue block or slide is received, and patient identifiers are cross-checked with the clinical requisition form to ensure absolute accuracy.
• Deparaffinization and Rehydration: The ultra-thin tissue sections (typically 3 to 5 micrometers thick) mounted on charged glass slides are heated and treated with solvents like xylene and descending grades of alcohol to remove the paraffin wax and rehydrate the tissue.
• Antigen Retrieval: The formalin fixation process can mask target proteins. To reverse this, slides undergo Heat-Induced Epitope Retrieval (HIER) using specialized microwave or pressure cooker systems, or Proteolytic Induced Epitope Retrieval (PIER) using enzymes, restoring the accessibility of the antigens.
• Blocking and Antibody Incubation: Endogenous enzymes are blocked to prevent false-positive staining. The slides are then incubated with highly specific primary antibodies, followed by secondary antibodies linked to a chromogenic detection system.
• Chromogen Development and Counterstaining: The chromogen substrate is applied, producing a visible colored precipitate. The slides are counterstained with hematoxylin to provide contrast by coloring cell nuclei blue, then dehydrated and coverslipped.
• Microscopic Evaluation: The Consultant Pathologist examines the slides under a high-resolution light microscope, assessing the staining pattern (nuclear, cytoplasmic, or membranous) and the percentage of positive cells.

When is a Chromo Immunohistochemistry Performed?

Classification of Undifferentiated Tumors

When a tumor is highly aggressive or poorly differentiated, its cells lose their normal structural characteristics, making it impossible to identify the tissue of origin using standard microscopic examination. Physicians request Chromo Immunohistochemistry to determine whether the tumor is a carcinoma (epithelial origin), sarcoma (mesenchymal origin), lymphoma (hematopoietic origin), or melanoma (melanocytic origin). By applying a panel of lineage-specific antibodies, pathologists can definitively classify the tumor, which is crucial because the treatment protocols for these cancers differ fundamentally.

Determination of the Primary Site in Metastatic Disease

In many oncological cases, a patient presents with metastatic cancer—cancer that has spread to organs like the liver, lungs, bones, or brain—without an obvious primary tumor. Chromo IHC is performed on the metastatic tissue biopsy to identify the primary site of origin. Pathologists utilize specific organ-associated markers, such as Thyroid Transcription Factor-1 (TTF-1) for lung or thyroid cancer, CDX2 for colorectal cancer, and Mammaglobin or GATA3 for breast cancer, allowing targeted treatment of the primary malignancy.

Prognostic and Predictive Biomarker Evaluation

Chromo Immunohistochemistry is routinely performed to evaluate specific biomarkers that predict how a disease will progress and how it will respond to targeted therapies. In breast cancer, for example, IHC is used to assess Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) status. Patients with ER/PR-positive tumors benefit from hormone therapy, while those with HER2-positive tumors are candidates for anti-HER2 targeted drugs like trastuzumab, making this test vital for personalized oncology.

Identification of Specific Infectious Pathogens

Beyond oncology, Chromo IHC is a powerful tool for detecting infectious agents within tissue specimens when standard cultures or stains are inconclusive. It is highly sensitive in identifying viral proteins (such as Cytomegalovirus, Herpes Simplex Virus, or Epstein-Barr Virus), bacterial antigens (such as Helicobacter pylori in gastric biopsies), and fungal structures. This direct visualization of pathogens in association with tissue inflammation confirms active infection rather than simple colonization.

Distinguishing Benign from Malignant Lesions

In borderline or highly complex cases, distinguishing between a benign, pre-cancerous lesion and an invasive malignancy can be challenging. Chromo IHC assists pathologists by highlighting specific cellular structures, such as the presence or absence of a basal cell layer. In prostate and breast biopsies, the loss of the basal cell layer—demonstrated by negative staining for markers like p63 or high molecular weight cytokeratins—confirms invasive carcinoma, whereas its preservation indicates a benign or in situ lesion.

What Does a Chromo Immunohistochemistry Detect?

Chromo Immunohistochemistry is capable of detecting a vast array of cellular proteins, receptors, and molecular markers. At Test Zone Diagnostic Center, our comprehensive IHC panels are designed to identify key diagnostic indicators, including:

• Estrogen Receptor (ER): Evaluates hormone sensitivity in breast carcinomas.
• Progesterone Receptor (PR): Assesses hormone receptor status to guide endocrine therapy.
• HER2/neu (ErbB2): Detects oncogene amplification in breast and gastric cancers.
• Ki-67: Measures cellular proliferation rates, indicating tumor aggressiveness.
• Cytokeratin 7 (CK7): Identifies epithelial cells, typically positive in lung, breast, and ovarian cancers.
• Cytokeratin 20 (CK20): Positive in gastrointestinal tract, transitional cell, and Merkel cell carcinomas.
• Thyroid Transcription Factor-1 (TTF-1): Confirms primary lung adenocarcinoma or thyroid origin.
• CDX2: A nuclear marker highly specific for intestinal epithelial differentiation and colorectal adenocarcinoma.
• Prostate-Specific Antigen (PSA): Confirms prostatic origin in metastatic epithelial tumors.
• S100 Protein: Detects neuroectodermal tissues, highly sensitive for melanoma and neural tumors.
• Melan-A (MART-1): A highly specific marker for melanocytic differentiation and melanoma.
• CD20: Identifies B-lymphocytes, crucial for diagnosing B-cell non-Hodgkin lymphomas.
• CD3: Identifies T-lymphocytes, essential for classifying T-cell malignancies.
• Leukocyte Common Antigen (LCA / CD45): Distinguishes hematolymphoid neoplasms from carcinomas and sarcomas.
• Synaptophysin: Detects neuroendocrine differentiation in various neuroendocrine tumors.
• Chromogranin A: Works alongside synaptophysin to confirm neuroendocrine neoplasms.
• CD117 (c-KIT): Diagnostic marker for Gastrointestinal Stromal Tumors (GIST).
• Desmin: Identifies muscle differentiation, useful in diagnosing rhabdomyosarcomas and leiomyosarcomas.
• Smooth Muscle Actin (SMA): Detects smooth muscle cells and myofibroblasts.
• Calretinin: A highly sensitive marker for mesothelial cells, helping diagnose mesothelioma.
• p63: Highlights basal cells in prostate and breast tissues to rule out invasive carcinoma.
• p16 (INK4a): Serves as a surrogate marker for high-risk Human Papillomavirus (HPV) infection.
• Vimentin: Expressed in mesenchymal cells, positive in most sarcomas and melanomas.
• E-cadherin: Evaluates cell adhesion; loss of expression is characteristic of lobular breast carcinoma.
• CD30: Diagnostic marker for Hodgkin lymphoma and anaplastic large cell lymphoma.

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center, we understand that waiting for pathology results can be an anxious time for patients and their families. Because Chromo Immunohistochemistry involves complex, multi-stage laboratory processing, antigen retrieval, antibody incubation, and detailed microscopic evaluation by our Consultant Pathologists, the turnaround time is typically 3 to 5 working days. This timeline ensures that every step of the quality control process is meticulously followed to deliver the most accurate results.

Once the diagnostic report is finalized and signed off by our specialist pathologist, patients receive an automated SMS notification. Reports can be accessed securely online through the Test Zone Diagnostic Center patient portal, allowing you to view, download, and print your results from the comfort of your home. Physical copies of the reports, along with the stained slides and paraffin blocks, can also be collected directly from our main center in Sargodha, Pakistan, or delivered via our dedicated courier service upon request.

Chromo Immunohistochemistry Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Hormone Receptors (ER/PR)	Negative or low expression in normal non-target tissues.	Strong nuclear positivity in hormone-receptor-positive breast carcinomas.
HER2/neu Expression	Negative (Score 0 or 1+) in normal epithelial cells.	Overexpression (Score 3+) indicating HER2-positive breast or gastric malignancy.
Ki-67 Proliferation Index	Low percentage of positive nuclei (typically < 5%) in resting tissues.	Elevated index (> 20% to 90%) indicating rapid cell division and aggressive tumor behavior.
Lineage Markers (LCA / CD45)	Positive only in normal inflammatory/immune cells.	Diffuse, strong positivity in lymphoma or leukemia cells infiltrating tissues.
Epithelial Markers (CK7 / CK20)	Expression restricted to specific normal epithelial linings.	Abnormal coordinate expression patterns (e.g., CK7+/CK20-) indicating specific primary carcinomas.
Basal Cell Layer (p63 / CK5/6)	Continuous, intact basal layer in normal breast ducts and prostate glands.	Complete absence or disruption of the basal layer, confirming invasive carcinoma.
Neuroendocrine Markers (Synaptophysin)	Negative in non-neuroendocrine tissues.	Strong cytoplasmic positivity confirming neuroendocrine tumor or carcinoma.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for Chromo Immunohistochemistry?

• Experienced healthcare professionals: Our pathology department is led by highly qualified Consultant Pathologists with specialized training in histopathology and immunohistochemistry.
• Patient-focused care: We prioritize patient well-being, offering compassionate support, clear guidance, and seamless sample handling throughout the diagnostic journey.
• Quality diagnostic services: Test Zone Diagnostic Center adheres to strict national and international quality control standards, ensuring diagnostic reproducibility and accuracy.
• Professional reporting: Our reports provide comprehensive clinical details, including marker intensity, localization, and percentage positivity, to guide oncologists effectively.
• Modern diagnostic approach: We utilize advanced automated staining platforms that minimize human error and ensure highly consistent, standardized staining quality.
• Comfortable environment: Our state-of-the-art facility in Sargodha provides a clean, comfortable, and professional environment for patients and families.
• Convenient location: Situated in a highly accessible area of Sargodha, Pakistan, we ensure easy sample drop-off and report collection for patients across the region.
• Commitment to accurate diagnosis: We are dedicated to delivering precise, evidence-based diagnostic insights that form the foundation of successful clinical outcomes.